FDA Considerations for Ketamine Tablet

FDA considerations for ketamine tablet come down to one fact above all others: no oral ketamine tablet has ever received FDA approval, for depression, pain, or any other use. The agency has approved ketamine only in an injectable form, Ketalar, cleared in 1970 as a surgical anesthetic, and it has approved esketamine, a related but distinct molecule, as the nasal spray Spravato for treatment-resistant depression. Every ketamine tablet, troche, or capsule a patient takes today comes from a compounding pharmacy operating under a doctor's prescription, not from an FDA-approved manufacturer. That single distinction shapes the drug's legal status, how prescribers can talk about it, and whether an insurer will pay for it.

For background on how these tablets and troches are made and dispensed, see our overview of ketamine tablet basics.

Current Regulatory Status

What the FDA Has Approved

• Ketalar (ketamine hydrochloride injection): approved in 1970 as a general anesthetic for surgical and diagnostic procedures, injectable administration only.
• Spravato (esketamine nasal spray): approved in 2019 for treatment-resistant depression and in 2020 for major depressive disorder with acute suicidal ideation or behavior. Esketamine is the S-enantiomer of ketamine, a single mirror-image form of the ketamine molecule that carries its own separate FDA approval and dosing requirements.

You can confirm current approval status for any drug through the FDA's own Drugs@FDA database. No ketamine tablet product appears there.

Off-Label Use Is Legal

Off-label prescribing means using an FDA-approved drug for an indication, population, dose, or route of administration not listed on its approved label. It is legal in the United States and based on a prescriber's clinical judgment rather than direct FDA regulation of the prescribing decision itself. Medical literature estimates that off-label prescribing accounts for about 20 percent of outpatient prescriptions written nationwide. When a physician prescribes ketamine tablet for depression or chronic pain, they are practicing legal off-label medicine, and the prescriber, not the FDA, takes on responsibility for that individual risk-benefit call.

Manufacturers Cannot Promote Off-Label Use

While off-label prescribing by a doctor is legal, the FDA prohibits drug manufacturers from marketing a product for uses outside its approved label. Ketalar's manufacturer cannot promote injectable ketamine for oral psychiatric use. That restriction is one reason no pharmaceutical company has yet pushed an FDA-approved oral ketamine product through to market: building a commercial case for an off-label molecule requires going through a formal approval pathway first.

DEA Scheduling and Prescribing Rules

Ketamine is a Schedule III controlled substance under the Controlled Substances Act, a federal classification for drugs with an accepted medical use and a moderate potential for abuse or dependence. According to the DEA Diversion Control Division, Schedule III status carries specific prescribing rules: a prescriber needs a valid DEA registration to prescribe the drug, prescriptions can cover up to a 90-day supply unless state law sets a shorter limit, refills are allowed up to five times within six months, and prescriptions can be transmitted electronically, by phone for oral prescriptions, or in writing depending on state rules.

During the COVID-19 public health emergency, the DEA allowed telehealth prescribing of controlled substances without a prior in-person exam. Those flexibilities have been extended multiple times, and permanent telehealth rules for controlled substances remained unresolved as of 2024.

Compounding Under Section 503A

Because no FDA-approved ketamine tablet exists, patients get ketamine tablet, troches, or capsules through compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act, a provision that lets state-licensed pharmacies prepare individualized medications from a valid prescription without going through the full new drug approval process. A 503A pharmacy must compound from a prescription written for a named patient, use pharmaceutical-grade ingredients from registered suppliers, follow USP compounding standards (USP 795 governs non-sterile preparations), hold a state pharmacy board license, and avoid producing what amounts to a commercial copy of an already-approved product.

The "Essentially a Copy" Question

The FDA has taken the position that compounding a drug that is essentially a copy of an FDA-approved product is not permitted under 503A. Because injectable ketamine, Ketalar, is FDA-approved, this created some uncertainty around compounded ketamine. In practice, the FDA's enforcement attention has focused on sterile, injectable products rather than oral forms that differ in route and formulation. Compounded ketamine tablet troches and capsules have continued to be available, and this practice has not drawn FDA enforcement action to date.

503B Outsourcing Facilities

503B facilities are outsourcing pharmacies that operate under closer FDA oversight than standard 503A pharmacies and can produce compounded medications in larger batches. Some 503B facilities have made ketamine-containing products, and how far 503B ketamine compounding should extend remains an active regulatory question.

FDA Concerns About Ketamine Clinic Oversight

The FDA has flagged concerns about the rapid growth of ketamine clinics and at-home ketamine programs, specifically around patient screening and selection, the adequacy of monitoring during and after treatment, the risk of diversion of compounded ketamine, and the quality of compounded preparations used in these settings. The FDA and DEA have run joint education and enforcement efforts aimed at keeping ketamine prescribing within appropriate medical frameworks.

Paths to a Future FDA-Approved Ketamine Tablet

A few distinct routes could eventually produce an FDA-approved oral ketamine product.

• New Drug Application (NDA): the formal application a company files with the FDA to win marketing approval for a new drug, based on clinical trial data proving safety and efficacy for a specific formulation and indication, such as maintaining antidepressant response in treatment-resistant depression. It is the most resource-intensive route but produces a fully approved, insurable product. Several companies were developing oral ketamine formulations as of 2024, including extended-release options aimed at depression maintenance.
• Breakthrough Therapy Designation: an FDA program that speeds up development and review for drugs treating serious conditions when early evidence suggests a substantial improvement over existing therapies. Ketamine tablet for treatment-resistant depression could potentially qualify, given the documented unmet need.
• 505(b)(2) Pathway: an approval route that lets an applicant rely partly on published literature and the FDA's prior findings about a related approved drug instead of generating every safety and efficacy dataset from scratch. For ketamine tablet, a sponsor could lean on the existing body of pharmacokinetic and clinical data to reduce the research burden.

References

• StatPearls: Ketamine, NCBI Bookshelf clinical reference on ketamine pharmacology and mechanisms of action
• PubChem: Ketamine Compound Summary, NCBI chemical database entry with molecular data and pharmacokinetics
• MedlinePlus, National Library of Medicine consumer drug information site
• FDA Drugs@FDA, searchable database of approved drug products and therapeutic equivalents